drugset / Trial / NCT04699604
A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)
Phase 3
Completed
55 enrolled
Bridgette Jones
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, crossover study comparing asthma control post treatment in African American/Black and Caucasian/White children in both hyper and hypo responsive HILD (Histamine Lontophoresis with Laser Doppler monitoring) phenotypes with uncontrolled persistent allergic asthma using Levocetirizine (LTZ) vs placebo.
Timeline
- Start
- 2021-04-28
- Primary completion
- 2026-04-15
- Completion
- 2026-04-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Levocetirizine | Unknown | 2.5 mg | Oral |
| Comparator | Levocetirizine | Unknown | 5 mg | Oral |